Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients
Authors:
- 1 August 2016
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (8) , 1612-1619
Abstract
Background Unintentional weight loss occurs among advanced non-small cell lung cancer (NSCLC) patients and is associated with worse survival. Small studies have suggested that weight gain during treatment is associated with superior survival. Patients and Methods A retrospective analysis analyzed data from three international phase III studies comprising 2301 advanced, nonsquamous NSCLC patients who received a platinum-based, first-line doublet, with or without bevacizumab and maintenance therapy. Body weight was recorded before and after treatment by each study's schedule. The relationship between weight gain and overall survival (OS) and progression-free survival (PFS) was assessed using log-rank test and adjusted Cox modeling. Logistic regression assessed the association between baseline covariates and post-baseline weight gain. Results 421 (18.3%) patients had >5% weight gain after baseline. More than half of the weight gain cohort exhibited initial weight gain by 3 weeks. Median OS was 16.7 months versus 10.7 months for the >5% versus ≤5% weight gain subgroup (N=1880) (pConclusions Weight gain during treatment may be an early indicator of clinical benefit. If confirmed in prospective studies, monitoring weight change may provide important information regarding survival outcomes in NSCLC and may provide ideas for new therapeutic strategies.Keywords
Funding Information
- Eli Lilly and Company
This publication has 23 references indexed in Scilit:
- Impact of Weight Change During the Course of Concurrent Chemoradiation Therapy on Outcomes in Stage IIIB Non-Small Cell Lung Cancer Patients: Retrospective Analysis of 425 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung CancerClinical Lung Cancer, 2013
- Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass IndexJournal of Clinical Oncology, 2013
- Weight Gain in Advanced Non–Small-Cell Lung Cancer Patients During Treatment With Split-Course Concurrent Chemoradiotherapy Is Associated With Superior SurvivalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Obesity and Weight Loss at Presentation of Lung Cancer are Associated with Opposite Effects on SurvivalJournal of Surgical Research, 2011
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?British Journal of Cancer, 2004
- Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancerLung Cancer, 2001
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980